-
Endo Pharmaceuticals Inc. et al v. Actavis Inc. et al DC CAFC
- 1:13-cv-00436
- S.D.N.Y.
- Judge: J. Paul Oetken
+1
- Filed: 01/18/2013
- Closed: 06/29/2016
- Latest Docket Entry: 03/07/2019
- PACER
2
Plaintiffs
3
Defendants
1
Accused
Product
5
Patents-in-Suit
1,259
Days in
Litigation
-
Endo Pharmaceuticals Inc. et al v. Actavis Inc. et al DC CAFC
- 1:13-cv-00436
- S.D.N.Y.
- Judge: J. Paul Oetken
+1
- Filed: 01/18/2013
- Closed: 06/29/2016
- Latest Docket Entry: 03/07/2019
- PACER
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A thermoformed dosage form comprising: i) one or more active ingredients with abuse potential (A) selected from the group consisting of opiates and opioids, ii) optionally physiologically acceptable auxiliary substances (B), iii) at least 30% by
view more
|
Invalid (102 and 103)
Entry 117 |
2 |
The dosage form according to claim 1, which is in the form of a tablet.
|
Invalid (102 and 103)
Entry 117 |
5 |
A process for the production of a dosage form according to claim 1, said process comprising mixing components (A), the optionally present component (B), component (C) and the optionally present component (D) to form a mixture and, optionally after
view more
|
Invalid (102 and 103)
Entry 117 |
7 |
A dosage form obtained by the process of claim 5.
|
Invalid (102 and 103)
Entry 117 |
8 |
The dosage form according to claim 1, wherein the active ingredient with abuse potential (A) is oxycodone or a physiologically acceptable salt thereof.
|
Invalid (102 and 103)
Entry 117 |
-
Infringement
Actavis Incorporated
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of Wellbutrinb XLGeneric versions of Xanax Cardizem CD | US 7,851,482 B2 |
4
|
Infringement
Entry 59Entry 58 |
Cardizem CDGeneric versions of Wellbutrinb XLGeneric versions of Wellbutrinb XL, Xanax, Cardizem CDXanax | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 183Entry 142 Entry 96 |
Cardizem CDGeneric versions of Wellbutrinb XLXanax | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 142Entry 96 |
Actavis South Atlantic LLC
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of Wellbutrinb XLGeneric versions of Xanax Cardizem CD | US 7,851,482 B2 |
4
|
Infringement
Entry 59Entry 58 |
Cardizem CDGeneric versions of Wellbutrinb XLGeneric versions of Wellbutrinb XL, Xanax, Cardizem CDXanax | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 183Entry 142 Entry 96 |
Cardizem CDGeneric versions of Wellbutrinb XLXanax | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 142Entry 96 |
Watson Pharmaceuticals, Inc.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of Wellbutrinb XLGeneric versions of Xanax Cardizem CD | US 7,851,482 B2 |
4
|
Infringement
Entry 59Entry 58 |
Cardizem CDGeneric versions of Wellbutrinb XLGeneric versions of Wellbutrinb XL, Xanax, Cardizem CDXanax | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 183Entry 142 Entry 96 |
Cardizem CDGeneric versions of Wellbutrinb XLXanax | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 142Entry 96 |